Chemistry:LY-367,265

From HandWiki
Short description: Chemical compound
LY-367,265
LY-367265 structure.png
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
Chemical and physical data
FormulaC24H25FN4O2S
Molar mass452.55 g·mol−1
3D model (JSmol)

LY-367,265 is a drug developed by Eli Lilly, which acts as both a potent and selective antagonist at the serotonin 5-HT2A receptor, and also a selective serotonin reuptake inhibitor (SSRI). It has antidepressant effects in animal studies, reduces glutamate signalling in the brain and increases the analgesic effects of morphine.[1][2][3]

References

  1. "LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone". European Journal of Pharmacology 407 (1–2): 39–46. October 2000. doi:10.1016/S0014-2999(00)00728-7. PMID 11050288. 
  2. "Potential antidepressant LY 367265 presynaptically inhibits the release of glutamate in rat cerebral cortex". Synapse 55 (3): 156–63. March 2005. doi:10.1002/syn.20104. PMID 15602751. 
  3. "Effects of fluoxetine and LY 367265 on tolerance to the analgesic effect of morphine in rats". Acta Physiologica Hungarica 98 (2): 205–13. June 2011. doi:10.1556/APhysiol.98.2011.2.12. PMID 21616779.